A Medical Device Daily

Curative Health Services (CHS; Hauppauge, New York) reported that it and certain individual plaintiffs have entered into a settlement with the California Department of Health Services (DHS; Sacramento) in connection with suits filed against DHS challenging reimbursement methodology for blood clotting factor implemented in June 2004.

DHS has agreed to process, on a priority basis, all pending and future Medi-Cal, California Children's Services and Genetically Handicapped Persons Program claims submitted by CHS, the company said. In addition, DHS has agreed to expedite its efforts to implement electronic billing and payment for blood clotting factor claims.

Paul McConnell, president and CEO of CHS, said, “The priority processing should result in a reduction of our California-related days sales outstanding to approximately 60 days and a meaningful improvement in the company's cash flow.“

CHS delivers care and clinical results for patients with serious or chronic medical conditions. Its Specialty Infusion business, through its national footprint of Critical Care Systems' local pharmacy branches, provides products, related clinical services and disease management support to patients with chronic or severe conditions. Its Wound Care Management business manages a nationwide network of wound care center programs.

In other legalities, Swissray (Elizabeth, New Jersey) reported a settlement with the U.S. District Court for the Eastern District of New York. Terry Ross, chairman and CEO of Swissray, said, “The terms of that settlement are confidential between and among the parties.“

Swissray is a supplier of direct digital radiography (ddR) technology providing radiographic images in seconds without the use of film, imaging plates, cassettes or chemical processing.